6-K
false2024-06-302024Q20001809196--12-31“Short-term deposits” are classified within the balance sheet item “Other financial assets”. Other current/non-current assets comprise mainly of accrued interest and deposits. 0001809196 2024-06-30 0001809196 2023-12-31 0001809196 2024-04-01 2024-06-30 0001809196 2023-04-01 2023-06-30 0001809196 2024-01-01 2024-06-30 0001809196 2023-01-01 2023-06-30 0001809196 2023-06-30 0001809196 2022-12-31 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001809196 imtx:BmsAndModernaCollaborationAgreementMember 2024-04-01 2024-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2024-04-01 2024-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2024-04-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2024-04-01 2024-06-30 0001809196 srt:BoardOfDirectorsChairmanMember 2024-04-01 2024-06-30 0001809196 imtx:RentalLandMember 2024-04-01 2024-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2023-04-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-04-01 2023-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2023-04-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2023-04-01 2023-06-30 0001809196 ifrs-full:OtherReservesMember 2024-01-01 2024-06-30 0001809196 ifrs-full:RetainedEarningsMember 2024-01-01 2024-06-30 0001809196 ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2024-01-01 2024-06-30 0001809196 imtx:NonInterestBearingLiabilityMember 2024-01-01 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-01-01 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ConvertedOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember imtx:GrantedOnJuneTwoThousandAndTwentyFourMember 2024-01-01 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:GrantedOnJuneTwoThousandAndTwentyFourMember 2024-01-01 2024-06-30 0001809196 imtx:ConvertedOptionsMember imtx:GrantedOnJuneTwoThousandAndTwentyMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001809196 ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OrdinarySharesMember ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OrdinarySharesMember ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember country:DE 2024-01-01 2024-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2024-01-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2024-01-01 2024-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2024-01-01 2024-06-30 0001809196 srt:BoardOfDirectorsChairmanMember 2024-01-01 2024-06-30 0001809196 imtx:OfficeEquipmentAndInstallationsMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OtherReservesMember 2023-01-01 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-01-01 2023-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001809196 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2023-01-01 2023-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2023-01-01 2023-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:OtherCurrentNonCurrentAssetsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:TradeReceivablesMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:CashAndCashEquivalentsMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember ifrs-full:LeaseLiabilitiesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember imtx:LiabilitiesForWarrantsMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:OtherCurrentLiabilitiesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:AccountsPayablesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2024-06-30 0001809196 ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2024-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2024-06-30 0001809196 imtx:ReorganizationMember 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-06-30 0001809196 imtx:ConvertedOptionsMember 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheTwoMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheThreeMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheOneMember 2024-06-30 0001809196 imtx:CashAndCashEquivalentsMember 2024-06-30 0001809196 imtx:LiabilitiesForWarrantsMember 2024-06-30 0001809196 imtx:OtherCurrentLiabilitiesMember 2024-06-30 0001809196 imtx:AccountsPayablesMember 2024-06-30 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2024-06-30 0001809196 ifrs-full:TradeReceivablesMember 2024-06-30 0001809196 imtx:ShorttermDepositsMember 2024-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember 2024-06-30 0001809196 ifrs-full:TopOfRangeMember 2024-06-30 0001809196 imtx:CollaborationAgreementMember 2024-06-30 0001809196 ifrs-full:OtherAssetsMember 2024-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:CashAndCashEquivalentsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:OtherCurrentNonCurrentAssetsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:TradeReceivablesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember imtx:LiabilitiesForWarrantsMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:OtherCurrentLiabilitiesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:AccountsPayablesMember 2023-12-31 0001809196 ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2023-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001809196 imtx:ReorganizationMember 2023-12-31 0001809196 imtx:ShorttermDepositsMember 2023-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001809196 imtx:LiabilitiesForWarrantsMember 2023-12-31 0001809196 imtx:OtherCurrentLiabilitiesMember 2023-12-31 0001809196 imtx:AccountsPayablesMember 2023-12-31 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2023-12-31 0001809196 ifrs-full:TradeReceivablesMember 2023-12-31 0001809196 imtx:CashAndCashEquivalentsMember 2023-12-31 0001809196 ifrs-full:BottomOfRangeMember 2023-12-31 0001809196 ifrs-full:OtherAssetsMember 2023-12-31 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-02-07 2024-02-07 0001809196 imtx:PerformanceBasedOptionsMember 2024-02-07 2024-02-07 0001809196 imtx:PerformanceBasedOptionsMember imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember 2024-02-07 2024-02-07 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-01-01 2023-12-31 0001809196 imtx:RegisteredDirectOfferingMember 2024-01-22 0001809196 ifrs-full:MajorOrdinaryShareTransactionsMember imtx:PublicOfferingMember 2024-01-22 0001809196 imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:IssuedCapitalMember imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:SharePremiumMember imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:MajorOrdinaryShareTransactionsMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:SharePremiumMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:IssuedCapitalMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 imtx:AuthorizationOfFinancialStatementsMember 2024-08-13 2024-08-13 0001809196 imtx:GenmabCollaborationAgreementMember 2024-01-01 2024-03-31 0001809196 ifrs-full:BottomOfRangeMember 2024-03-31 0001809196 ifrs-full:BottomOfRangeMember 2023-03-31 0001809196 ifrs-full:TopOfRangeMember 2023-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-03-06 2024-03-06 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-06-25 2024-06-25 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2020-07-01 2020-07-01 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2020-07-01 0001809196 ifrs-full:BottomOfRangeMember 2022-12-31 0001809196 ifrs-full:IssuedCapitalMember 2023-12-31 0001809196 ifrs-full:OtherReservesMember 2023-12-31 0001809196 ifrs-full:RetainedEarningsMember 2023-12-31 0001809196 ifrs-full:SharePremiumMember 2023-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2023-12-31 0001809196 imtx:ConvertedOptionsMember 2023-12-31 0001809196 imtx:MatchingStockOptionsMember 2023-12-31 0001809196 imtx:PerformanceBasedOptionsMember 2023-12-31 0001809196 ifrs-full:IssuedCapitalMember 2024-06-30 0001809196 ifrs-full:SharePremiumMember 2024-06-30 0001809196 ifrs-full:RetainedEarningsMember 2024-06-30 0001809196 ifrs-full:OtherReservesMember 2024-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-12-31 0001809196 ifrs-full:SharePremiumMember 2022-12-31 0001809196 ifrs-full:RetainedEarningsMember 2022-12-31 0001809196 ifrs-full:OtherReservesMember 2022-12-31 0001809196 ifrs-full:IssuedCapitalMember 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-06-30 0001809196 ifrs-full:OtherReservesMember 2023-06-30 iso4217:EUR iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:EUR xbrli:shares iso4217:USD xbrli:shares utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule
13a-16
or
15d-16
of the Securities Exchange Act of 1934
August 13, 2024
Commission File Number:
001-39363
 
 
IMMATICS N.V.
 
 
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of Principal Executive Office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒    Form
40-F ☐
 
 
 

INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On August 13, 2024, Immatics N.V. (the “Company”) issued an interim report for the three- and
six-month
periods ended June 30, 2024, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2024 financial results for the Company, which is attached hereto as Exhibit 99.2.
INCORPORATION BY REFERENCE
This Report on Form
6-K
(other than Exhibit 99.2
)
including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form
S-8
(Registration Nos.
333-249408,
333-265820
and
333-280935)
and the registration statements on Form
F-3
(Registration Nos.
333-240260
and
333-274218)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBITS
 
Exhibit Number
  
Description
99.1
  
99.2
  
101.INS
  
XBRL Taxonomy Extension Instance Document
101.SCH
  
XBRL Taxonomy Extension Schema Document
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
  
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
 
1

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report
to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
IMMATICS N.V.
Date: August 13, 2024     by:  
/s/ Harpreet Singh
      Harpreet Singh
      Chief Executive Officer
 
2